Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: A simulation for the EU G5 countries

Ivo L Abraham, Lucy Han, Diana Sun, Karen Macdonald, Matti Aapro

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Aim: We simulated the budget impact of biosimilar erythropoiesis- stimulating agent (ESA) in EU G5 countries. Materials & methods: Three models were built to estimate the number of patients who could be provided with antineoplastic therapy with rituximab, bevacizumab or trastuzumab from cost savings of biosimilar erythropoietin use in a hypothetical panel of 100,000 patients. The associated number of patients needed to convert to biosimilar ESA to provide such treatments was also calculated. Results: Under fixed dosing, the savings from 100% conversion were €110,592,159, translating into an additional 9770 rituximab, 3912 bevacizumab, or 3713 trastuzumab treatments. Under weight-based dosing, the savings from 100% conversion were €146,170,333, corresponding to an additional 12,913 rituximab, 5171 bevacizumab or 4908 trastuzumab treatments. The number of patients needed to convert ranged from four to 51. Conclusion: Using biosimilar ESA for supportive cancer care yields significant savings and increases accessibility to primary antineoplastic therapy in a budget neutral way.

Original languageEnglish (US)
Pages (from-to)1599-1609
Number of pages11
JournalFuture Oncology
Volume10
Issue number9
DOIs
StatePublished - 2014

Fingerprint

Epoetin Alfa
Biosimilar Pharmaceuticals
Cost Savings
Antineoplastic Agents
Anemia
Hematinics
Budgets
Therapeutics
Erythropoietin
Weights and Measures

Keywords

  • antineoplastic therapy
  • biosimiar
  • budgetary impact
  • cancer
  • chemotherapy-induced anemia
  • epoetin alfa
  • EU
  • simulation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment : A simulation for the EU G5 countries. / Abraham, Ivo L; Han, Lucy; Sun, Diana; Macdonald, Karen; Aapro, Matti.

In: Future Oncology, Vol. 10, No. 9, 2014, p. 1599-1609.

Research output: Contribution to journalArticle

@article{b35c8126ecd741cf933eb1920409f4a4,
title = "Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: A simulation for the EU G5 countries",
abstract = "Aim: We simulated the budget impact of biosimilar erythropoiesis- stimulating agent (ESA) in EU G5 countries. Materials & methods: Three models were built to estimate the number of patients who could be provided with antineoplastic therapy with rituximab, bevacizumab or trastuzumab from cost savings of biosimilar erythropoietin use in a hypothetical panel of 100,000 patients. The associated number of patients needed to convert to biosimilar ESA to provide such treatments was also calculated. Results: Under fixed dosing, the savings from 100{\%} conversion were €110,592,159, translating into an additional 9770 rituximab, 3912 bevacizumab, or 3713 trastuzumab treatments. Under weight-based dosing, the savings from 100{\%} conversion were €146,170,333, corresponding to an additional 12,913 rituximab, 5171 bevacizumab or 4908 trastuzumab treatments. The number of patients needed to convert ranged from four to 51. Conclusion: Using biosimilar ESA for supportive cancer care yields significant savings and increases accessibility to primary antineoplastic therapy in a budget neutral way.",
keywords = "antineoplastic therapy, biosimiar, budgetary impact, cancer, chemotherapy-induced anemia, epoetin alfa, EU, simulation",
author = "Abraham, {Ivo L} and Lucy Han and Diana Sun and Karen Macdonald and Matti Aapro",
year = "2014",
doi = "10.2217/fon.14.43",
language = "English (US)",
volume = "10",
pages = "1599--1609",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "9",

}

TY - JOUR

T1 - Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment

T2 - A simulation for the EU G5 countries

AU - Abraham, Ivo L

AU - Han, Lucy

AU - Sun, Diana

AU - Macdonald, Karen

AU - Aapro, Matti

PY - 2014

Y1 - 2014

N2 - Aim: We simulated the budget impact of biosimilar erythropoiesis- stimulating agent (ESA) in EU G5 countries. Materials & methods: Three models were built to estimate the number of patients who could be provided with antineoplastic therapy with rituximab, bevacizumab or trastuzumab from cost savings of biosimilar erythropoietin use in a hypothetical panel of 100,000 patients. The associated number of patients needed to convert to biosimilar ESA to provide such treatments was also calculated. Results: Under fixed dosing, the savings from 100% conversion were €110,592,159, translating into an additional 9770 rituximab, 3912 bevacizumab, or 3713 trastuzumab treatments. Under weight-based dosing, the savings from 100% conversion were €146,170,333, corresponding to an additional 12,913 rituximab, 5171 bevacizumab or 4908 trastuzumab treatments. The number of patients needed to convert ranged from four to 51. Conclusion: Using biosimilar ESA for supportive cancer care yields significant savings and increases accessibility to primary antineoplastic therapy in a budget neutral way.

AB - Aim: We simulated the budget impact of biosimilar erythropoiesis- stimulating agent (ESA) in EU G5 countries. Materials & methods: Three models were built to estimate the number of patients who could be provided with antineoplastic therapy with rituximab, bevacizumab or trastuzumab from cost savings of biosimilar erythropoietin use in a hypothetical panel of 100,000 patients. The associated number of patients needed to convert to biosimilar ESA to provide such treatments was also calculated. Results: Under fixed dosing, the savings from 100% conversion were €110,592,159, translating into an additional 9770 rituximab, 3912 bevacizumab, or 3713 trastuzumab treatments. Under weight-based dosing, the savings from 100% conversion were €146,170,333, corresponding to an additional 12,913 rituximab, 5171 bevacizumab or 4908 trastuzumab treatments. The number of patients needed to convert ranged from four to 51. Conclusion: Using biosimilar ESA for supportive cancer care yields significant savings and increases accessibility to primary antineoplastic therapy in a budget neutral way.

KW - antineoplastic therapy

KW - biosimiar

KW - budgetary impact

KW - cancer

KW - chemotherapy-induced anemia

KW - epoetin alfa

KW - EU

KW - simulation

UR - http://www.scopus.com/inward/record.url?scp=84906572793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906572793&partnerID=8YFLogxK

U2 - 10.2217/fon.14.43

DO - 10.2217/fon.14.43

M3 - Article

C2 - 25145430

AN - SCOPUS:84906572793

VL - 10

SP - 1599

EP - 1609

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 9

ER -